in-PharmaTechnologist.com presents its periodic round-up of personnel changes in the pharmaceutical sector.
Wex Pharmaceuticals has appointed Dr Jean Bourgouin to the position of chief scientific officer. In this capacity Bourgouin will oversee the clinical development of Tectin, Wex's lead product, and take overall responsibility for R&D.
Bourgouin has over 25 years of global clinical drug development experience in the pharmaceutical industry, most recently as vice president of medical affairs at Bradmer Pharmaceuticals.
He has already previously worked at Wex, holding the post of chief medical officer from March 2005 to March 2006. Earlier in his career he spent time as vice president of scientific affairs at Sanofi-Aventis Canada for eight years.
Amy Cohen has been appointed to the post of vice president, clinical operations at EyeGate Pharma, a privately held pharmaceutical company using non-invasive delivery techniques to treat serious ocular diseases.
Cohen has worked in clinical development for more than 20 years, most recently as director, clinical operations at Javelin Pharmaceuticals. Prior to this she was program manager, clinical trials/medical affairs at Becton, Dickinson and Company.
She has also held clinical operations leadership positions at Boston Scientific and Biogen Idec.
US-based Anesiva has appointed Michael Kranda as president, CEO and a member of the company's board of directors.
Kranda has two decades of commercial operating and corporate development experience, most recently as managing director of biotechnology and life science investments at Vulcan.
Prior to this he served as CEO of Oxford GlycoSciences and was also president and CEO of Immunex.
William Sheridan has been appointed as the new chief medical officer at BioCryst Pharmaceuticals, a company specialising in the crystallography and structure-based drug design. Sheridan most recently held the post of vice president of North American medical affairs.
Chelsea Therapeutics International has appointed Joseph Oliveto to the post of vice president of operations. In this capacity Oliveto will take responsibility for project management, manufacturing, and operational aspects of commercialization activity for Droxidopa.
Oliveto has nearly 20 years of global pharmaceutical experience in the areas of licensing, project management, clinical development and manufacturing, including a spell at Hoffmann-La Roche.
Alpharma has revamped its executive leadership team, with appointments made for key positions. Ron Warner has been appointed executive vice president and chief scientific officer, taking responsibility for late-stage development projects and dealings with regulatory bodies.
In addition Scott Shively has been appointed senior vice president, pharmaceutical commercial operations. This post gives Shively responsibility for the pharmaceutical supply chain, alliance management and the Company's operations in Ireland.